Grants Archive - Page 158 of 180 - Kenneth Rainin Foundation

Crohn’s disease and ulcerative colitis are part of the group called inflammatory bowel disease (IBD), a medical condition where the immune system is causing severe intestinal and colonic inflammation leading to severe complications. Former therapies rely on suppressing the immune system but modern treatments, so-called biological treatments, are blocking certain steps in disease progression or […]

Eicosanoids are signaling molecules that contribute to both the development and resolution of inflammation. Inflammasomes are immune sensors that help to trigger immune responses to infection. Tuft cells are specialized cells of the intestinal lining that are important during infection with parasitic worms. Eicosanoids and inflammasomes have been separately implicated in IBD, although the underlying […]

The cause of Inflammatory Bowel Disease (IBD) is unknown, but intestinal bacteria—involved in the production of molecules that impact health—are widely accepted to play a key role. A significant proportion of IBD patients with pouches (surgically created rectums after the diseased colon is removed) continue to have inflammation similar to their previous disease, whereas non-IBD […]

According to the Montreal classification, ulcerative colitis (UC) disease scope varies from how much of the colon is affected, with lesser colon involvement called proctitis (E1) and extensive disease called pancolitis (E3). These differing extents impact rates of hospitalization, chance of colectomy, and cancer risk. When the extent of UC is limited (E1 or E2) […]

The cause of Inflammatory Bowel Disease (IBD) is unknown, but intestinal bacteria—involved in the production of molecules that impact health—are widely accepted to play a key role. A significant proportion of IBD patients with pouches (surgically created rectums after the diseased colon is removed) continue to have inflammation similar to their previous disease, whereas non-IBD […]

According to the Montreal classification, ulcerative colitis (UC) disease scope varies from how much of the colon is affected, with lesser colon involvement called proctitis (E1) and extensive disease called pancolitis (E3). These differing extents impact rates of hospitalization, chance of colectomy, and cancer risk. When the extent of UC is limited (E1 or E2) […]